Equities research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Down 1.3 %
NASDAQ AEZS opened at $1.95 on Friday. The stock has a market capitalization of $9.48 million, a PE ratio of -0.57 and a beta of 1.57. Aeterna Zentaris has a 52 week low of $1.36 and a 52 week high of $3.38. The firm has a 50 day moving average of $1.95 and a two-hundred day moving average of $1.90.
Aeterna Zentaris Company Profile
See Also
- Five stocks we like better than Aeterna Zentaris
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- The Charles Schwab Company Can Hit New Highs
- Where Do I Find 52-Week Highs and Lows?
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.